| 1 |
32699265 | Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma. | 2021 Feb |
2 |
| 2 |
34159680 | The BAFF/NFκB axis is crucial to interactions between sorafenib-resistant HCC cells and cancer-associated fibroblasts. | 2021 Sep |
5 |
| 3 |
34366674 | Sorafenib in the Treatment of Virus-Related HCC: Differences Between HCV and HBV. | 2021 |
1 |
| 4 |
34634203 | Biomimetic Synthesis of Lavandiolides H, I, and K and Artematrolide F via Diels-Alder Reaction. | 2021 Nov 5 |
1 |
| 5 |
32149026 | Identification and validation of potential key long noncoding RNAs in sorafenib-resistant hepatocellular carcinoma cells. | 2020 |
2 |
| 6 |
32169577 | Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma. | 2020 |
1 |
| 7 |
32210579 | HANR Enhances Autophagy-Associated Sorafenib Resistance Through miR-29b/ATG9A Axis in Hepatocellular Carcinoma. | 2020 |
7 |
| 8 |
32724415 | Comprehensive analysis of circulating microRNAs as predictive biomarkers for sorafenib therapy outcome in hepatocellular carcinoma. | 2020 Aug |
1 |
| 9 |
33234725 | Exploring the mechanism of resistance to sorafenib in two hepatocellular carcinoma cell lines. | 2020 Nov 21 |
1 |
| 10 |
30476722 | Cytokine augments the sorafenib-induced apoptosis in Huh7 liver cancer cell by inducing mitochondrial fragmentation and activating MAPK-JNK signalling pathway. | 2019 Feb |
1 |
| 11 |
30765873 | Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma. | 2019 Mar |
1 |
| 12 |
31385002 | Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma. | 2019 Oct |
1 |
| 13 |
31465134 | Activation of EGFR-KLF4 positive feedback loop results in acquired resistance to sorafenib in hepatocellular carcinoma. | 2019 Nov |
1 |
| 14 |
31686512 | Amphiphilic Polypeptoids Rupture Vesicle Bilayers To Form Peptoid-Lipid Fragments Effective in Enhancing Hydrophobic Drug Delivery. | 2019 Nov 26 |
1 |
| 15 |
28833396 | A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma. | 2018 Jan |
2 |
| 16 |
29251327 | Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib. | 2018 Feb |
1 |
| 17 |
29805309 | Chemical and genetic inhibition of STAT3 sensitizes hepatocellular carcinoma cells to sorafenib induced cell death. | 2018 |
1 |
| 18 |
30127933 | Arsenic trioxide and sorafenib combination therapy for human hepatocellular carcinoma functions via up-regulation of TNF-related apoptosis-inducing ligand. | 2018 Sep |
3 |
| 19 |
30321984 | Emodin Sensitizes Hepatocellular Carcinoma Cells to the Anti-Cancer Effect of Sorafenib through Suppression of Cholesterol Metabolism. | 2018 Oct 12 |
1 |
| 20 |
27982429 | MicroRNA-125a-5p Is a Downstream Effector of Sorafenib in Its Antiproliferative Activity Toward Human Hepatocellular Carcinoma Cells. | 2017 Jul |
1 |
| 21 |
28350139 | Upregulation of miR-137 reverses sorafenib resistance and cancer-initiating cell phenotypes by degrading ANT2 in hepatocellular carcinoma. | 2017 Apr |
6 |
| 22 |
28414325 | Hedgehog signaling pathway affects the sensitivity of hepatoma cells to drug therapy through the ABCC1 transporter. | 2017 Jul |
2 |
| 23 |
28874716 | Cell Spheroids with Enhanced Aggressiveness to Mimic Human Liver Cancer In Vitro and In Vivo. | 2017 Sep 5 |
1 |
| 24 |
28900541 | Simultaneous silencing of ACSL4 and induction of GADD45B in hepatocellular carcinoma cells amplifies the synergistic therapeutic effect of aspirin and sorafenib. | 2017 |
1 |
| 25 |
26790028 | Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells. | 2016 Apr |
2 |
| 26 |
27184800 | Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib. | 2016 May 16 |
1 |
| 27 |
27367026 | Sirtuin 3 enhanced drug sensitivity of human hepatoma cells through glutathione S-transferase pi 1/JNK signaling pathway. | 2016 Aug 2 |
1 |
| 28 |
27484637 | Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy. | 2016 Oct |
2 |
| 29 |
25463538 | Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion. | 2015 Apr |
1 |
| 30 |
25850433 | Integrated Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) and Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) Quantitative Proteomic Analysis Identifies Galectin-1 as a Potential Biomarker for Predicting Sorafenib Resistance in Liver Cancer. | 2015 Jun |
5 |
| 31 |
26460271 | Sorafenib inhibits cancer side population cells by targeting c‑Jun N‑terminal kinase signaling. | 2015 Dec |
1 |
| 32 |
26516583 | FTY720 (Fingolimod) sensitizes hepatocellular carcinoma cells to sorafenib-mediated cytotoxicity. | 2015 Oct |
3 |
| 33 |
23543326 | Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases. | 2014 Mar |
3 |
| 34 |
24692700 | Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-catenin pathways. | 2014 Apr |
1 |
| 35 |
25057499 | Hepatic stellate cell coculture enables sorafenib resistance in Huh7 cells through HGF/c-Met/Akt and Jak2/Stat3 pathways. | 2014 |
5 |
| 36 |
25349646 | Role of autophagy in differential sensitivity of hepatocarcinoma cells to sorafenib. | 2014 Oct 27 |
1 |
| 37 |
23724146 | Recombinant human acid sphingomyelinase as an adjuvant to sorafenib treatment of experimental liver cancer. | 2013 |
2 |
| 38 |
23769634 | PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation. | 2013 Nov |
2 |
| 39 |
23877009 | Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells. | 2013 Oct |
1 |
| 40 |
21858812 | Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. | 2012 Aug 1 |
1 |
| 41 |
22261591 | PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation. | 2012 Aug |
3 |
| 42 |
22753710 | The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment. | 2012 Jul |
1 |
| 43 |
22801548 | Molecular mechanisms of sorafenib action in liver cancer cells. | 2012 Aug 1 |
2 |
| 44 |
22811581 | Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. | 2012 Sep 15 |
1 |
| 45 |
21205925 | Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. | 2011 Apr |
9 |
| 46 |
21187475 | PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. | 2010 Dec |
3 |